CS
TXG icon

Credit Suisse’s 10x Genomics TXG Stock Holding History

Credit Suisse’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,000
Closed -$284K – 4562
2020
Q4 		$284K Buy
+2,000
New +$290K ﹤0.01% 4001

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Credit Suisse's TXG Position: Q1 2024 in Review

Credit Suisse increased its 10x Genomics (TXG) stake by 17% in Q1 2024, buying an estimated $9.07M and bringing the position to 1,456,428 shares worth $54.7M. The position accounts for 0.05% of the portfolio, ranked #343.

Credit Suisse first reported a position in TXG in Q4 2019 and has held it in 18 quarters since. The position peaked at $256M in Q2 2021. 290 funds tracked by Wall St. Rank hold TXG as of Q1 2024.

  • Credit Suisse held 1,456,428 shares of 10x Genomics worth $54.7M as of Q1 2024.
  • Credit Suisse bought 206,326 10x Genomics shares in Q1 2024, an estimated $9.07M.
  • 10x Genomics made up 0.05% of Credit Suisse's portfolio in Q1 2024, its #343 holding.
  • Credit Suisse first reported a position in 10x Genomics in Q4 2019 and has held it in 18 quarters since.
  • Credit Suisse's 10x Genomics position peaked at $256M in Q2 2021.
  • 290 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.